Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Update KEYNOTE-716: aanhoudend voordeel pembrolizumab bij melanoom
mrt 2024 | Dermato-oncologie